Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently …
L Broadbent, H Groves, MD Shields… - Influenza and other …, 2015 - Wiley Online Library
As the most important viral cause of severe respiratory disease in infants and increasing
recognition as important in the elderly and immunocompromised, respiratory syncytial virus ( …
recognition as important in the elderly and immunocompromised, respiratory syncytial virus ( …
The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study
HE Groves, PP Piché-Renaud, A Peci… - The Lancet Regional …, 2021 - thelancet.com
Background The ongoing coronavirus disease 2019 (COVID-19) pandemic has resulted in
implementation of public health measures worldwide to mitigate disease spread, including; …
implementation of public health measures worldwide to mitigate disease spread, including; …
Respiratory viral infection alters the gut microbiota by inducing inappetence
Respiratory viral infections are extremely common, but their impacts on the composition and
function of the gut microbiota are poorly understood. We previously observed a significant …
function of the gut microbiota are poorly understood. We previously observed a significant …
[HTML][HTML] What can early Canadian experience screening for COVID-19 teach us about how to prepare for a pandemic?
…, K Katz, JE Powis, W Ng, V Williams, H Groves… - Cmaj, 2020 - Can Med Assoc
… Powis, Wil Ng, Victoria Williams, Michelle Science, Helen Groves, Mathew P. Muller, Alon
Vaisman, Susy Hota, Jennie Johnstone and Jerome A. Leis … Helen Groves reports an …
Vaisman, Susy Hota, Jennie Johnstone and Jerome A. Leis … Helen Groves reports an …
Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide
…, JM Gutierrez, C Bundalovic-Torma, HE Groves… - Scientific reports, 2020 - nature.com
The COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2), was declared on March 11, 2020 by the World Health Organization. As of …
2 (SARS-CoV-2), was declared on March 11, 2020 by the World Health Organization. As of …
Enhanced IL-2 in early life limits the development of TFH and protective antiviral immunity
CJ Pyle, L Labeur-Iurman, HT Groves, F Puttur… - Journal of Experimental …, 2021 - rupress.org
T follicular helper cell (T FH )–dependent antibody responses are critical for long-term
immunity. Antibody responses are diminished in early life, limiting long-term protective immunity …
immunity. Antibody responses are diminished in early life, limiting long-term protective immunity …
Respiratory disease following viral lung infection alters the murine gut microbiota
HT Groves, L Cuthbertson, P James… - Frontiers in …, 2018 - frontiersin.org
Alterations in the composition of the gut microbiota have profound effects on human health.
Consequently, there is great interest in identifying, characterizing, and understanding factors …
Consequently, there is great interest in identifying, characterizing, and understanding factors …
Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2
…, ML Aldrich, DL Goldman, HE Groves… - Journal of the …, 2021 - academic.oup.com
Background Although coronavirus disease 2019 (COVID-19) is a mild infection in most
children, a small proportion develop severe or critical illness. Data describing agents with …
children, a small proportion develop severe or critical illness. Data describing agents with …
The differential impact of pediatric COVID-19 between high-income countries and low-and middle-income countries: A systematic review of fatality and ICU admission …
…, H Hibino, B Camara, M Isabel, L Cho, HE Groves… - PloS one, 2021 - journals.plos.org
Background The overall global impact of COVID-19 in children and regional variability in
pediatric outcomes are presently unknown. Methods To evaluate the magnitude of global …
pediatric outcomes are presently unknown. Methods To evaluate the magnitude of global …
Multicenter initial guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2
…, M Aldrich, DL Goldman, HE Groves… - Journal of the …, 2020 - academic.oup.com
Background Although coronavirus disease 2019 (COVID-19) is mild in nearly all children, a
small proportion of pediatric patients develop severe or critical illness. Guidance is therefore …
small proportion of pediatric patients develop severe or critical illness. Guidance is therefore …
